Clinical trial Recruiting at 1 site Observational

Natural history of nemaline myopathy in Spain

Official title: Natural History Study for Patients With Nemaline Myopathy in Spain

Run by Hospital Universitari Vall d'Hebron Research Institute · NCT07488806 · Data updated 2026-11-12

This program will follow people in Spain who have nemaline myopathy to chart how the condition changes over time and collect clinical, genetic, and functional data for future trials.

More Idiopathic Inflammatory Myopathies trials

Quick facts

Study typeObservational
SexAll
Enrollment100 (estimated)
SponsorHospital Universitari Vall d'Hebron Research Institute
Academic / other
Locations1 site (Barcelona)
StatusRecruiting
StartedJune 2026
Main results expectedJune 2031
Study endsJune 2032
Registry record updatedMarch 23, 2026
Trial IDNCT07488806 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are people in Spain with a confirmed clinical and genetic diagnosis of nemaline myopathy (or a compatible muscle biopsy) who can give informed consent and attend visits at the study center.

Probably not a fit

Patients seeking immediate access to disease-modifying therapies, those without a confirmed diagnosis, or those unable to travel to Barcelona are unlikely to receive direct therapeutic benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational natural history program enrolls patients with genetically or clinically confirmed nemaline myopathy in Spain to collect retrospective and prospective clinical data. Participants undergo detailed phenotyping including genetic testing, muscle ultrasound, motor function scales, respiratory and cardiac assessments, quality-of-life and neuropsychological measures. The project will track disease progression, define genotype–phenotype relationships, and seek reliable biomarkers and outcome measures for future therapeutic trials. Data collection is standardized to align with international efforts and to facilitate long-term follow-up and recruitment for interventional studies.

Why it matters

Potential benefit: If successful, the program could speed development of treatments by defining outcome measures, identifying biomarkers, and improving patient selection for future clinical trials.

How similar studies have gone: Natural history efforts in other countries for nemaline myopathy and related congenital myopathies have produced useful genotype–phenotype data and trial-ready outcome measures, but NM-specific datasets remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with a confirmed clinical and genetic diagnosis of MN (mutations in ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, TNNT3), or under discussion if they only have a compatible biopsy.
* Signed informed consent by the patient or Legal Authority Responsible, and/or assent by the subject (in pediatric population).

Where it's running

  • University Hospital Vall d'Hebron
    Barcelona, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.